Page last updated: 14 September 2021
The PBAC is an independent expert body appointed by the Australian Government. Members include doctors, health professionals, health economists and consumer representatives.
Its primary role is to recommend new medicines for listing on the PBS. No new medicine can be listed unless the committee makes a positive recommendation. The PBAC meets three times a year, usually in March, July and November.
When recommending a medicine for listing, the PBAC takes into account the medical conditions for which the medicine was registered for use in Australia, its clinical effectiveness, safety and cost-effectiveness (‘value for money’) compared with other treatments.
PBAC has two sub-committees to assist with analysis and advice in these areas:
Contact details for the PBAC can be found in PBS Contacts
Agendas, outcomes and public summary documents of PBAC meetings can be found under elements of the listing process
Professor Andrew Wilson is the Chair of the PBAC. He has specialist professional qualifications in clinical medicine and public health medicine and a PhD in epidemiology.
Ms Jo Watson is the Deputy Chair of the PBAC. She is also the Chair of the Health Technology Assessment Consumer Consultative Committee, Deputy Chair of the Consumers Health Forum, and a long standing consumer nominee and advocate.
Dr Peggy Brown is a psychiatrist from Queensland and is a Fellow of the Australian and New Zealand College of Psychiatrists.
Ms Michelle Burke is the industry nominee. She has more than 20 years of experience in the pharmaceutical industry, contributing in areas which include access to medicines and industry development.
Professor Jonathan Craig is the Vice President and Executive Dean of the College of Medicine & Public Health at Flinders University, SA. He is also the President of the Australia-NZ Society of Nephrology, a member of the National Health and Medical Research Council (NHMRC) Advisory Group on the Synthesis and Translation of Research Evidence and a member of Medical Services Advisory Committee (MSAC).
Professor Christopher Etherton-Beer is a clinical academic in Geriatric Medicine at the University of Western Australia and is a Geriatrician/ Clinical Pharmacologist at Royal Perth Hospital. Professor Etherton-Beer has research interests in ageing and aged care, stroke, medical education and pharmaco-geriatrics. He is also Chair of the Drug Utilisation Sub Committee of the PBAC.
Dr Peter Fox is a medical oncologist in central west New South Wales. He is an oncology clinical trial investigator, and has an interest in equity of access to health care in rural areas. He is a senior lecturer at Western Sydney University.
Associate Professor Peter Grimison is a medical oncologist at the Chris O’Brien Lifehouse in Sydney, and conducts clinical research at the University of Sydney.
Associate Professor (Peter) Shane Hamblin is the head of unit, Endocrinology and Diabetes for Western Health, Melbourne and is also a consultant endocrinologist at the Alfred Hospital. He also has current university appointments with the University of Melbourne and Monash University.
Professor Catherine Hill is a senior consultant rheumatologist at the Queen Elizabeth and Royal Adelaide Hospitals. She is also a current member of the Drug Utilisation Sub-Committee of the PBAC, with extensive experience in epidemiology.
Dr Amanda Johnston is a clinical and laboratory Haematologist at Westmead Hospital, Sydney.
Professor Kirsten Howard is a Professor of Health Economics at the School of Public Health, University of Sydney. She is also Chair of the Economics Sub-Committee of the PBAC, with extensive experience in the health economics field.
Professor Clement Loy is a clinical epidemiologist and cognitive neurologist at the University of Sydney. He is Director of the Huntington Disease Service, Westmead Hospital Sydney.
Dr Susannah Morris is a social policy expert by profession who works as health consumer advocate and representative with particular interests and experience in the field of cancer care.
Dr Jo-Anne Manski-Nankervis is a general practitioner and Senior Lecturer in Primary Care at the University of Melbourne. She is a Fellow of the Royal Australian College of General Practitioners (RACGP).
Dr Elizabeth Marles is a former President of the Royal Australian College of General Practitioners. She is a senior staff specialist in general practice and Director of the Hornsby-Brooklyn GP Unit and is a Fellow of the Royal Australian College of General Practitioners (RACGP).
Dr Kylie Mason is a clinical and laboratory haematologist at the Royal Melbourne Hospital and an National Health and Medical Research Council (NHMRC) Clinical Research Fellow at the University of Melbourne.
Associate Professor David Newby is a community pharmacist in Newcastle, and an academic in the Discipline of Pharmacy and Experimental Pharmacology, School of Biomedical Sciences and Pharmacy, at the University of Newcastle.
Dr Meena Okera is a medical oncologist at the Adelaide Cancer Centre. She is also a Fellow of the Royal Australasian College of Physicians with extensive experience and involvement to the development of the Northern Territory Cancer Plan.
Dr Ray Parkin is a consultant physician and cardiologist in Bathurst NSW, who has many years’ experience working in rural and regional health centres. He also has a postgraduate qualifications in Bioethics and Drug Development, and has co-ordinated a number of Phase II/III trials in Australia.
Dr Thomas Snelling is an infectious diseases consultant at the Princess Margaret Hospital (Perth). He is also the Scientific Director of the Wesfarmers Centre of Vaccines and Infectious Diseases at the Telethon Kids Institute.